Core Viewpoint - BriaCell Therapeutics Corp. has completed a transaction where its subsidiary, BriaPro Therapeutics Corp., acquired the exclusive license to develop and commercialize Soluble CD80 (sCD80) for cancer treatment, which is expected to enhance cancer care through novel immunotherapy approaches [1][3][10]. Group 1: Transaction Details - BriaPro acquired worldwide rights to develop and commercialize sCD80, while the University of Maryland retains certain rights, with BriaPro obligated to pay 2% royalties upon commercialization [3]. - BriaCell has provided BriaPro with up to $3 million in a Credit Facility to support research and development, subject to BriaCell's approval [4]. - As part of the transaction, BriaPro issued 23,972,589 Common Shares to BriaCell, valued at approximately C$1.18 million, increasing BriaCell's ownership in BriaPro to about 78% [5][11]. Group 2: Leadership and Governance - Jamieson Bondarenko was appointed as Chairman of BriaPro's board following the transaction, bringing extensive experience in investment banking and corporate development [6]. - The transaction received overwhelming approval from 99.81% of disinterested shareholders of BriaPro, ensuring compliance with minority security holder protection regulations [7]. Group 3: Research and Development Potential - The technology behind sCD80, developed by Dr. Suzanne Ostrand-Rosenberg, has shown promise in animal models by halting tumor growth and potentially restoring anti-tumor immunity [2]. - BriaCell aims to explore the use of sCD80 in combination with other immunotherapies, highlighting its potential as a transformative treatment for cancer patients [10].

Core Insights - AVAX One Technology Ltd. reported significant growth in revenue and operational developments for the fourth quarter and full year ended December 31, 2025, driven by its new Avalanche digital asset treasury strategy [2][5]. Financial Performance - Total revenue for Q4 2025 reached $1.1 million, a substantial increase from approximately $27,000 in Q4 2024, primarily due to staking rewards and Bitcoin mining [5][19]. - Total operating expenses in Q4 2025 were $16.8 million, up from $2.1 million in Q4 2024, largely due to a $7.8 million non-cash unrealized loss on digital assets and a $5.6 million impairment related to intellectual property [5][19]. - The net loss for Q4 2025 was $16.6 million, or $(4.11) per diluted share, compared to a net loss of approximately $1.9 million, or $(12.69) per diluted share, in Q4 2024 [5][19]. Operational Highlights - The company completed approximately 3.3 million share repurchases under a $40 million program, reflecting confidence in its intrinsic value [2][5]. - As of March 31, 2026, AVAX One holds approximately 13.9 million AVAX, supporting its treasury strategy [1][2]. - The company launched an institutional-grade Avalanche treasury dashboard for real-time visibility into portfolio metrics [5]. Strategic Initiatives - AVAX One aims to scale its operations as a leading public market gateway to the Avalanche ecosystem, focusing on AVAX accumulation, yield generation, and disciplined capital allocation [7]. - The company has engaged Treehouse to enhance yield generation on AVAX holdings, deploying over 800,000 AVAX into liquid staking infrastructure [5]. 2026 Guidance - The company projects full-year 2026 revenue between $11 million and $12 million, with an expected EBITDA of $2 million to $3 million, assuming specific prices for Bitcoin and Avalanche [6].

Core Viewpoint - Aqua Metals, Inc. has made significant advancements in 2025, focusing on the commercialization of its AquaRefining™ technology, expanding its product offerings, strengthening its financial position, and enhancing its role in the domestic critical minerals supply chain [1][3]. Technology Advancement and Product Expansion - The company refined its commercialization strategy for its first AquaRefining™ Campus (ARC) and expanded capabilities across lithium, nickel, and mixed hydroxide products [2]. - Achieved a major milestone by producing the first cathode active material made from 100% domestically sourced, recycled nickel, which is undergoing qualification by a tier-one battery manufacturer [6]. - Demonstrated pilot-scale processing of lithium iron phosphate (LFP) battery materials into battery-grade lithium carbonate, showcasing a viable recycling pathway [6]. - Produced lithium carbonate with fluorine content below 30 ppm, representing best-in-class quality in the recycling sector [6]. - Expanded product platform with the development of nickel carbonate and initial samples aligned to partner requirements, creating additional revenue pathways [6]. Strategic Partnerships and Market Development - Continued engagement with Lion Energy on a potential transaction that could expand Aqua Metals' commercial platform and strategic reach across the battery value chain [6]. - Signed a multi-year supply agreement with 6K Energy for battery-grade nickel metal and lithium carbonate [12]. - Established a non-binding LOI with Westwin Elements for a potential supply of recycled nickel carbonate [12]. - Signed an MOU with Impossible Metals to evaluate seabed mineral collection combined with AquaRefining™ for critical minerals production [12]. - Showcased technology to leading battery industry stakeholders, validating market interest and engagement [12]. Financial and Corporate Progress - Strengthened liquidity through asset sales, reduced operating burn, and capital raises, eliminating long-term debt [12]. - Raised $13.0 million in October 2025, with total new funding of approximately $17.1 million, providing runway for advancing engineering and site selection for the first commercial-scale facility [12]. - Reported cash and cash equivalents of approximately $10.8 million as of December 31, 2025, compared to $4.1 million in 2024 [17]. - Executed a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement [12]. - Strengthened the Board of Directors and completed a CFO transition to align financial leadership with the company's growth phase [12]. Leadership, Governance, and Intellectual Property - Received a foundational U.S. patent covering critical aspects of its lithium battery recycling technology, enhancing the AquaRefining™ intellectual property portfolio [12]. - Filed a provisional patent application for an innovative low-cost leaching technology for mined manganese ores and deep-sea nodules [12].

Core Insights - Connect Biopharma announced positive topline data from its Phase 1 study of IV rademikibart in patients with asthma or COPD, demonstrating rapid improvement in forced expiratory volume in one second (FEV1) [5][2] - The company entered into a securities purchase agreement for $20.2 million equity financing, extending its cash runway into the second half of 2027 [6][2] Development Highlights - Rademikibart's Phase 2 Seabreeze STAT studies for acute asthma and COPD were initiated in 2025, with topline data expected mid-2026 [2][4] - The Phase 3 study results for rademikibart in moderate-to-severe atopic dermatitis (AD) showed rapid and durable efficacy, with ~90% of patients achieving near-maximal responses [4][5] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $44.3 million, which is expected to fund operations into the second half of 2027 [9][20] - For the three months ended December 31, 2025, the net loss was $15.1 million, or ($0.27) per share, compared to a net loss of $8.9 million, or ($0.16) per share for the same period in 2024 [9][18] Corporate Developments - The company has entered into a private placement agreement to sell 6,130,000 shares at $3.25 per share, with gross proceeds expected to be $20.2 million [6][2] - Connect Biopharma has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million [11][9]

Core Viewpoint - MDB Capital Holdings, LLC reported its financial and operational results for the fourth quarter and full year ended December 31, 2025, highlighting its focus on launching disruptive technology companies through a public venture platform [1][4]. Financial Results - For the year 2025, MDB Capital's annual fixed operating expenses were approximately $10 million, which included a $4 million investment in the MDB Direct/Public Ventures clearing platform and PatentVest [7]. - The net cash used for the full year was approximately $5.7 million, with year-end cash and current assets totaling around $22.3 million after liabilities [7]. Key Assets and Strategic Developments - MDB holds approximately 4.1 million shares and warrants in eXoZymes, valued at about $30 million based on market prices as of March 30, 2026, focusing on cell-free biomanufacturing [7]. - Paulex Bio successfully closed a $19 million seed round in 2025, with MDB holding approximately 7.1 million shares and warrants; clinical trials are expected to begin later this year, targeting an IPO in September 2026 [7]. - PatentVest is advancing towards becoming a standalone AI-enhanced IP law firm, leveraging a proprietary patent database and positioned for significant value creation in the legal-tech sector [7]. - MDB Direct is in discussions for a strategic partnership to enhance value from its self-clearing asset and expand distribution into individual-investor channels [7]. - Additional equity positions were earned in HeartBeam and Buda Juice through advisory services, positioning these companies for further growth [7].

Core Insights - Barfresh Food Group Inc. achieved record revenue of $5.4 million in Q4 2025 and $14.2 million for the full year, marking a 33% year-over-year growth driven by the acquisition of Arps Dairy [1][8] - The company provided Q1 2026 revenue guidance of $5.0 to $5.2 million, indicating up to 77% growth compared to the prior year [1][20] - Full year 2026 revenue guidance has been updated to $28 to $32 million, reflecting a conservative ramp-up schedule while still indicating substantial growth [1][21] Financial Performance - Q4 2025 revenue increased by 94% year-over-year to $5.4 million, up from $2.8 million in Q4 2024, primarily due to the Arps Dairy acquisition [3] - Full year 2025 revenue rose by 33% to $14.2 million from $10.7 million in 2024, driven by Arps Dairy's revenue, expanded school penetration, and seasonal traction with the Pop & Go product line [8] - Gross margin for Q4 2025 was 3%, down from 26% in Q4 2024, while adjusted gross margin was 4%, down from 30% in the prior year, due to production transition costs and different margin profiles from Arps Dairy [4][9] - The net loss for Q4 2025 improved to $763,000 from a loss of $852,000 in Q4 2024, while the full year net loss was $2.7 million, slightly better than the $2.8 million loss in 2024 [5][10] Operational Developments - The company secured $7.5 million in strategic financing to accelerate manufacturing expansion, allowing it to own its facility outright and support over $200 million in future revenue capacity [1][19] - The transition to a new 44,000-square-foot facility is expected to be completed by year-end 2026, which is anticipated to enhance operational efficiency and margin improvement [2][20] - The company has been approved for a $2.4 million government grant to purchase and install specialized equipment necessary for full-scale production operations [19] Future Outlook - For Q1 2026, Barfresh expects to achieve revenue between $5.0 million and $5.2 million and aims for Adjusted EBITDA breakeven [20] - The company anticipates fiscal year 2026 revenue growth of 97% to 125% compared to fiscal year 2025, driven by the full-year inclusion of Arps Dairy's revenue and growth of legacy products [21] - Adjusted EBITDA for fiscal year 2026 is projected to be between $3.2 million and $3.8 million, reflecting confidence in improving cash flow and operational scale [22]

Core Viewpoint - MaxCyte, Inc. has granted inducement awards to Parmeet Ahuja as part of his appointment as Chief Financial Officer, which includes stock options and restricted stock units (RSUs) [1] Group 1: Inducement Awards - The Compensation Committee granted stock options to purchase 375,000 shares and RSUs for 187,500 shares to Parmeet Ahuja [1] - The stock options have a ten-year term with an exercise price of $0.676, based on the closing price on March 30, 2026 [2] - The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal annual installments [3] Group 2: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [4] - The company utilizes Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [4] - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally [4]

Core Insights - NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. announced that an abstract for their investigational drug SIM0505 has been accepted for presentation at the ASCO 2026 meeting, highlighting its potential in treating advanced solid tumors, particularly platinum-resistant ovarian cancer [1][2]. Company Overview - NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, utilizing targeted therapies such as antibody-drug conjugates [4]. - Simcere Zaiming is an oncology-focused biopharmaceutical company, a subsidiary of Simcere Pharmaceutical Group Limited, established in 2023, dedicated to developing groundbreaking therapies for cancer patients globally [5]. Product Details - SIM0505 is a novel antibody drug conjugate targeting Cadherin-6 (CDH6) and features a proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity and improved therapeutic potential [3]. - The ongoing Phase 1 study (NCT06792552) is evaluating SIM0505's efficacy in advanced solid tumors, with a specific focus on platinum-resistant ovarian cancer [2][3].

Core Viewpoint - Lesaka Technologies, Inc. will release its third quarter 2026 results on May 6, 2026, after the U.S. market closes, followed by a presentation and Q&A session on May 7, 2026 [1] Group 1: Company Overview - Lesaka operates as a South African fintech company focused on providing financial services, software, and business services to underserved consumers and merchants in Southern Africa [4] - The company offers an integrated multiproduct platform that includes transactional accounts, lending, insurance, merchant acquiring, cash management, software, and Alternative Digital Products (ADP) [4] - Lesaka aims to facilitate the digitization of commerce in its markets through a full-service fintech platform within a connected ecosystem [4] Group 2: Financial Reporting and Events - The third quarter 2026 results will be available after the U.S. market closes on May 6, 2026 [1] - A presentation webcast and conference call will take place on May 7, 2026, at 8:00 AM EDT (2:00 PM SAST), including a live Q&A session for analysts and investors [1][2][3] - An archived version of the webcast will be accessible on Lesaka's Investor Relations website following the presentation [4]

Core Insights - BioAtla, Inc. reported its financial results for the full year and fourth quarter ended December 31, 2025, highlighting a focus on advancing its clinical programs while exploring strategic options to maximize shareholder value [1][3]. Corporate Updates - The company initiated a formal process to explore strategic options, including the potential sale of assets and partnerships, engaging Tungsten Advisors as its exclusive financial advisor [3]. - A reduction in force and cost-containment measures were implemented to align resources with near-term priorities, affecting the timing and scope of clinical development programs [4]. - The ongoing Phase 1 study of BA3182 in adenocarcinomas remains a priority, with the company committed to its clinical development despite potential delays [4]. Financial Results - Research and development (R&D) expenses for Q4 2025 were $8.0 million, down from $11.7 million in Q4 2024. For the full year, R&D expenses totaled $43.6 million, compared to $63.1 million in 2024, primarily due to lower program development costs and reduced headcount-related expenses [5]. - Collaboration and other revenue for Q4 2025 was $2.0 million, reflecting a milestone payment from Context Therapeutics, compared to $11.0 million for the full year 2024 [6]. - General and administrative (G&A) expenses decreased to $3.3 million in Q4 2025 from $4.6 million in Q4 2024, with full-year G&A expenses at $17.7 million compared to $21.8 million in 2024 [7]. - The net loss for Q4 2025 was $9.8 million, an improvement from a net loss of $14.9 million in Q4 2024. The full-year net loss was $59.6 million, down from $69.8 million in 2024 [8]. Cash Position - As of December 31, 2025, cash and cash equivalents were $7.1 million, a significant decrease from $49.0 million at the end of 2024 [10][23]. - The company expects to extend its runway through cost reductions and the utilization of a Standby Equity Purchase Agreement while pursuing strategic options [10]. Clinical Pipeline - BioAtla is advancing several clinical assets, including BA3182, a bispecific T-cell engager antibody for advanced adenocarcinoma, and Ozuriftamab Vedotin (Oz-V), targeting oropharyngeal squamous cell carcinoma [13][15]. - Oz-V has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck, with a potential market opportunity exceeding $7 billion [15]. Patent Portfolio - BioAtla holds extensive patent coverage for its CAB platform technology, with over 780 active patent matters, including more than 500 issued patents, covering various methods and compositions related to its product candidates [11].